What is the difference between BPC-157 and LL-37?

BPC-157: BPC-157 is believed to accelerate angiogenesis and upregulate growth hormone receptors locally at injury sites. LL-37: Human cathelicidin antimicrobial peptide; disrupts bacterial membranes and modulates innate immune response via TLR signaling

Is BPC-157 FDA approved?

BPC-157 is not FDA approved and restricted from compounding. It is discussed for research and educational purposes only, not as medical guidance.

How is BPC-157 administered in research settings?

In research settings, BPC-157 is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

How is LL-37 administered in research settings?

In research settings, LL-37 is typically administered via the subcutaneous, topical, or intravenous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›BPC-157 vs LL-37

Peptide Comparison

BPC-157 vs LL-37

Name: BPC-157 vs LL-37 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Tissue Repair peptides.

BPC-157

Body Protection Compound 157

RecoveryBanned from CompoundingResearch Only

Half-life: Under 30 minutes (plasma); no human PK data

635 providers listed

Full BPC-157 profile →

LL-37

cathelicidin

RecoveryResearch Only

Half-life: ~30 minutes

38 providers listed

Full LL-37 profile →

Bottom line

BPC-157 is carried by more providers on PeptideBase (635 vs 38); otherwise the two are closely matched on the measures we track.

Quick Verdict

BPC-157

Evidence

Emerging Clinical

Half-life

Under 30 minutes (plasma); no human PK data

LL-37

Evidence

Emerging Clinical

Half-life

~30 minutes

Which One Should You Choose?

Your goal	Better option
Oral administration option	BPC-157
Lower typical price per mg	BPC-157
More provider options (635 vs 38)	BPC-157

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

BPC-157

LL-37

Mechanism Family

Tissue Repair

Half-life

Under 30 minutes (plasma); no human PK data

~30 minutes

FDA Status

banned from compounding

nomination withdrawn

Admin Routes

subcutaneous, oral

subcutaneous, topical, intravenous

Availability

Research Only

Providers

635 listed

38 listed

FDA Update

Sep 2023

—

Avail. Notes

Not FDA-approved for any human use; sold as a research chemical; WADA prohibited (S0). Placed on the interim FDA 503A "Category 2" list (significant safety risks) in September 2023. In February 2026 HHS announced an intention to move several peptides toward "Category 1," but the FDA did not reclassify BPC-157. In April 2026 the FDA removed BPC-157 from the Category 2 list because the nomination was withdrawn — this does not authorize compounding, and BPC-157 is not on the 503A bulks list. The FDA's Pharmacy Compounding Advisory Committee is scheduled to review BPC-157 on July 23–24, 2026. Provider pricing varies by concentration, formulation, and source; use the PeptideBase directory to compare active providers and current availability.

Human cathelicidin antimicrobial peptide. Phase 1/2 trials for wound healing. No FDA approval, no NDA. Early investigational stage only. Not commercially available in US.

Research Evidence

BPC-157

Emerging ClinicalCohort study · 10 key studies · most recent 2026

LL-37

Emerging ClinicalCohort study · 19 key studies · most recent 2026

Research Citations

BPC-157

Cohort2026 · J Clin Med

Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery.

Cohort2026 · Sci Rep

Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.

Review2026 · Pharmaceutics

BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and…

Cohort2026 · Pharmaceuticals (Basel)

Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approac…

+6 more

LL-37

Cohort2026 · Front Immunol

Immunomodulatory effects of synthetic antimicrobial peptides on LPS-induced inflammatory responses in THP-1 m…

Cohort2026 · Children (Basel)

The Role of Vitamin D in Modulating the Innate Immune Response in Children with Vesicoureteral Reflux.

Cohort2026 · Proc Natl Acad Sci U S A

Antimicrobial peptoids pass rapidly through bacterial membranes and flocculate ribosomes and DNA: A single-ce…

Cohort2026 · Proc Natl Acad Sci U S A

Antimicrobial peptoids pass rapidly through bacterial membranes and flocculate ribosomes and DNA: A single-ce…

+15 more

About BPC-157

BPC-157 is believed to accelerate angiogenesis and upregulate growth hormone receptors locally at injury sites. It appears to promote fibroblast migration and collagen synthesis, contributing to faster tissue remodelling. Animal studies suggest systemic effects via modulation of the dopaminergic and serotonergic systems, though human data remain limited.

Research Areas

tissue repair across tendon, muscle, nerve, and gut — most broadly studied recovery peptideanti-inflammatory via COX-2 and NF-κB pathway modulationangiogenesis and wound healing via VEGF and nitric oxide system upregulationoral or subcutaneous administration studied — systemic and local tissue effects documented

About LL-37

Human cathelicidin antimicrobial peptide; disrupts bacterial membranes and modulates innate immune response via TLR signaling

Research Areas

antimicrobialimmune modulationwound healinganti-biofilm

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

BPC-157

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Regulatory Notes

global — WADA

BPC-157 is on the WADA Prohibited List at all times (S0, Non-Approved Substances), effective 1 January 2022. It has no FDA approval and no adequate human clinical trial.

source

LL-37

Reported (Unverified — Pending Clinical Review)

sepsis risk (may be pro-inflammatory at high doses)

No established clinical contraindications

Used Together?

BPC-157

GHK-Cu
Research suggests GHK-Cu and BPC-157 may produce complementary tissue repair and anti-inflammatory effects when combined. GHK-Cu is studied for copper-dependent collagen synthesis and antioxidant gene activation, while BPC-157 supports angiogenesis and growth factor expression.
TB-500
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.
Anticoagulants / blood thinners
Research notes that BPC-157 promotes angiogenesis and may influence platelet and vascular function in healing models. Combined use with anticoagulant medications may warrant monitoring. Consult your prescriber before combining.

Price (per mg)

BPC-157

$6.50/mg

$4.50 – $9.00 range

87 vendors

View price index →Find providers →

LL-37

$10.50/mg

$6.75 – $13.03 range

16 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

BPC-157

635 listed

Browse directory →

Providers offering

LL-37

38 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Tissue Repair Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 22, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). BPC-157 vs LL-37 — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/bpc-157/ll-37

https://peptidebase.io/peptides/compare/bpc-157/ll-37 Methodology License Download JSON Download CSV